Table 5.
30‐day thromboembolic % [95% CI; I 2] | 30‐day major bleeding % [95% CI; I 2] | 30‐day minor bleeding % [95% CI; I 2] | 30‐day overall mortality % [95% CI] | |
---|---|---|---|---|
Overall | 0.41% [0.29‐0.54; 0%] | 1.81% [0.84‐3.1; 92.4%] | 3.08% [1.02‐6.20; 97.7%] | 0.67% [0.29‐1.23] |
Dabigatran | 0.44% [0.26‐0.68; 0%] | 2.56% [0.92‐4.99; 76.9%] | 5.15% [2.21‐9.25; 85.2%] | 0.74% [0.24‐1.53] |
DOAC, Direct Oral Anticoagulant.